Part 1: When to test
PARP inhibition in the treatment of prostate cancer
23 Jul 2021
Part 2: Who to test
PARP inhibition in the treatment of prostate cancer
23 Jul 2021
Part 3: How to test
PARP inhibition in the treatment of prostate cancer
23 Jul 2021
Part 4: Metastatic prostate cancer and HRR defects
PARP inhibition in the treatment of prostate cancer
23 Jul 2021
Part 5: BRCA 1/2 mutations and prostate cancer
PARP inhibition in the treatment of prostate cancer
23 Jul 2021
The role of testing in prostate cancer treatment
Prof Phil Cornford, Dr Joaquin Mateo, Prof Alex Wyatt and Prof Derya Tilki
20 Jul 2021
Prostate cancer screening using prostate-specific antigen, a multiplex blood-tes...
Prof Martin Eklund - Karolinska Institutet, Solna, Sweden
20 Jul 2021
OncoAlert and ecancer weekly round up for July 12- July 18, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
19 Jul 2021
Mitomycin and BCG treatment vs BCG monotherapy in patients with non-muscle invas...
Dr Cosimo De Nunzio - Sant'Andrea Hospital, University La Sapienza, Rome, Italy
19 Jul 2021
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-...
Dr Michael Morris - Memorial Sloan Kettering Cancer Center and Weill Cornell Med...
15 Jul 2021
OncoAlert and ecancer weekly round up for July 1- July 10, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
13 Jul 2021
ASCO 2021: Precision and molecular reporting for prostate cancer
Prof Eleni Efstathiou - Houston Methodist Cancer Center, Houston, USA
29 Jun 2021
